DK0952215T3 - Protease til aktivering af koaguleringsfaktor VII - Google Patents
Protease til aktivering af koaguleringsfaktor VIIInfo
- Publication number
- DK0952215T3 DK0952215T3 DK99106913T DK99106913T DK0952215T3 DK 0952215 T3 DK0952215 T3 DK 0952215T3 DK 99106913 T DK99106913 T DK 99106913T DK 99106913 T DK99106913 T DK 99106913T DK 0952215 T3 DK0952215 T3 DK 0952215T3
- Authority
- DK
- Denmark
- Prior art keywords
- protease
- kda
- factor vii
- activating
- heparin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/38—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96447—Factor VII (3.4.21.21)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Materials Engineering (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19818495 | 1998-04-24 | ||
DE19827734 | 1998-06-22 | ||
DE19851335 | 1998-11-06 | ||
DE19851332 | 1998-11-06 | ||
DE19851336 | 1998-11-06 | ||
DE19903693A DE19903693A1 (de) | 1998-04-24 | 1999-02-01 | Protease zur Aktivierung des Gerinnungsfaktors VII |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0952215T3 true DK0952215T3 (da) | 2006-08-07 |
Family
ID=27545095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99106913T DK0952215T3 (da) | 1998-04-24 | 1999-04-08 | Protease til aktivering af koaguleringsfaktor VII |
Country Status (10)
Country | Link |
---|---|
US (4) | US6528299B1 (ja) |
EP (1) | EP0952215B1 (ja) |
JP (2) | JP4361986B2 (ja) |
KR (2) | KR100776921B1 (ja) |
AT (1) | ATE323157T1 (ja) |
AU (1) | AU748221B2 (ja) |
CA (1) | CA2269109C (ja) |
DE (2) | DE19903693A1 (ja) |
DK (1) | DK0952215T3 (ja) |
ES (1) | ES2262264T3 (ja) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19903693A1 (de) * | 1998-04-24 | 1999-10-28 | Centeon Pharma Gmbh | Protease zur Aktivierung des Gerinnungsfaktors VII |
DE19937219A1 (de) | 1999-08-06 | 2001-02-08 | Aventis Behring Gmbh | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie |
EP1023902A1 (en) | 1999-01-28 | 2000-08-02 | Aventis Behring Gesellschaft mit beschränkter Haftung | Pharmaceutical preparation for the treatment of inflammatory processes |
DE10023923A1 (de) | 1999-06-10 | 2000-12-14 | Aventis Behring Gmbh | Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen |
DE19937218A1 (de) * | 1999-08-06 | 2001-02-08 | Aventis Behring Gmbh | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie |
DE10238429A1 (de) | 2002-03-19 | 2003-10-30 | Aventis Behring Gmbh Intellect | Marburg I Mutante der Faktor VII aktivierenden Protease (FSAP) als Risikofaktor für Atherosklerose |
DE50108974D1 (de) * | 2000-07-26 | 2006-04-27 | Zlb Behring Gmbh | Mutanten der den Faktor VII aktivierenden Protease und Nachweisverfahren mit spezifischen Antikörpern |
US7153679B2 (en) | 2000-07-26 | 2006-12-26 | Aventis Behring Gmbh | Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis |
DE10036641A1 (de) * | 2000-07-26 | 2002-02-14 | Aventis Behring Gmbh | Monoklonale Antikörper für die den Blutgerinnungsfaktor VII aktivierende Protease (FSAP)und ihre Verwendung |
EP1226829B1 (de) * | 2001-01-08 | 2008-06-11 | CSL Behring GmbH | Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms |
EP2236618A3 (en) | 2001-01-31 | 2011-06-08 | Asahi Kasei Pharma Corporation | Compositions for assaying glycoprotein |
DE10148037A1 (de) * | 2001-09-28 | 2003-04-17 | Aventis Behring Gmbh | Verwendung der den Blutgerinnungsfaktor VII aktivierenden Protease zur Prophylaxe und Therapie von vaso-proliferativen Erkrankungen |
EP1458408B1 (en) | 2001-12-21 | 2009-04-15 | Novo Nordisk Health Care AG | Liquid composition of factor vii polypeptides |
DE10205520A1 (de) * | 2002-02-08 | 2003-08-14 | Aventis Behring Gmbh | Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease |
EP1517698B2 (en) | 2002-06-21 | 2017-12-06 | Novo Nordisk Health Care AG | STABILISED SOLID COMPOSITIONS OF FACTOR VIIa POLYPEPTIDES |
DE10309368A1 (de) * | 2002-08-06 | 2004-02-26 | Aventis Behring Gmbh Intellectual Property/Legal | Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase |
AU2003203246B2 (en) * | 2003-01-17 | 2009-10-22 | Ttc Co., Ltd. | Affinity trap reactor and single-step process for purifying angiostatin-like fragment from human plasma using the same |
US7897734B2 (en) | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
WO2004103398A1 (en) | 2003-05-23 | 2004-12-02 | Novo Nordisk Health Care Ag | Protein stabilization in solution |
EP1495766A1 (en) * | 2003-07-10 | 2005-01-12 | ZLB Behring GmbH | Factor VII activating protease (FSAP) derived polypeptides for the treatment of angiogenesis-related disorders |
EP1656158B1 (en) | 2003-08-14 | 2016-03-09 | Novo Nordisk Health Care AG | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
DE10346751A1 (de) * | 2003-10-06 | 2005-04-21 | Transmit Technologietransfer | Clot-Lysis-Assay |
EP2298287B1 (en) | 2003-12-19 | 2018-04-11 | Novo Nordisk Health Care AG | Stabilised compositions of factor VII polypeptides |
DE102005026163A1 (de) | 2004-08-24 | 2006-03-02 | Dade Behring Marburg Gmbh | Gegen den Marburg I Polymorphismus der Faktor VII aktivierenden Protease (FSAP) gerichtete Antikörper, ihre Herstellung und Verwendung |
ATE446377T1 (de) | 2005-12-22 | 2009-11-15 | Siemens Healthcare Diagnostics | Diagnostisches verfahren zur erkennung von trägern der marburg l-variante der faktor vii- aktivierenden protease (fsap) anhand differenzieller modulation der fsap-aktivität |
US20100172830A1 (en) * | 2007-03-29 | 2010-07-08 | Cellx Inc. | Extraembryonic Tissue cells and method of use thereof |
US8545459B2 (en) * | 2009-02-25 | 2013-10-01 | Teleflex Medical Incorporated | Stabilized enzyme compositions |
US9333280B2 (en) | 2009-02-25 | 2016-05-10 | Teleflex Medical Incorporated | Stabilized enzyme compositions |
EP2386652A1 (de) | 2010-05-12 | 2011-11-16 | Siemens Healthcare Diagnostics Products GmbH | Homogenes Verfahren zur Bestimmung der Plasminogenaktivator-aktivierenden Aktivität der FSAP |
KR102403299B1 (ko) | 2013-03-08 | 2022-06-03 | 체에스엘 베링 게엠베하 | 원격 허혈-재관류 손상의 치료 및 예방 |
KR20160026905A (ko) * | 2013-06-28 | 2016-03-09 | 체에스엘 베링 게엠베하 | 인자 xii 억제제 및 c1-억제제를 이용한 병용 치료요법 |
US10143413B2 (en) * | 2014-06-13 | 2018-12-04 | Kurin, Inc. | Catheter insertion device with blood analyzer |
US9820682B2 (en) | 2015-07-24 | 2017-11-21 | Kurin, Inc. | Blood sample optimization system and blood contaminant sequestration device and method |
US10827964B2 (en) | 2017-02-10 | 2020-11-10 | Kurin, Inc. | Blood contaminant sequestration device with one-way air valve and air-permeable blood barrier with closure mechanism |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4363319A (en) * | 1980-06-30 | 1982-12-14 | Applied Medical Devices, Inc. | Ready-to-use bandage incorporating a coagulant composition and method of preparing same |
FR2504921A1 (fr) * | 1981-04-30 | 1982-11-05 | Choay Sa | Medicament nouveau constitue par un complexe aprotinine-plasmine et procede de preparation de ce nouveau complexe |
US4447412A (en) * | 1983-02-01 | 1984-05-08 | Bilton Gerald L | Enzyme-containing digestive aid compostions |
US5175087A (en) * | 1987-07-06 | 1992-12-29 | Biopool International, Inc. | Method of performing tissue plasminogen activator assay |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
EP0482088B1 (en) * | 1989-07-20 | 1999-03-31 | Analytical Control Systems, Inc. | Improved stable coagulation controls |
HUT67693A (en) * | 1991-10-11 | 1995-04-28 | Novo Nordisk As | Hemostatic composition for arresting local bleedings |
WO1996010638A1 (en) * | 1994-09-30 | 1996-04-11 | Ppl Therapeutics (Scotland) Ltd. | Alpha-1-antitrypsin and antithrombine-iii variants |
US6359054B1 (en) * | 1994-11-18 | 2002-03-19 | Supratek Pharma Inc. | Polynucleotide compositions for intramuscular administration |
DE19903693A1 (de) * | 1998-04-24 | 1999-10-28 | Centeon Pharma Gmbh | Protease zur Aktivierung des Gerinnungsfaktors VII |
DE19937219A1 (de) * | 1999-08-06 | 2001-02-08 | Aventis Behring Gmbh | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie |
DE10023923A1 (de) * | 1999-06-10 | 2000-12-14 | Aventis Behring Gmbh | Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen |
DE19937218A1 (de) * | 1999-08-06 | 2001-02-08 | Aventis Behring Gmbh | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie |
DE50108974D1 (de) * | 2000-07-26 | 2006-04-27 | Zlb Behring Gmbh | Mutanten der den Faktor VII aktivierenden Protease und Nachweisverfahren mit spezifischen Antikörpern |
US7153679B2 (en) * | 2000-07-26 | 2006-12-26 | Aventis Behring Gmbh | Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis |
EP1226829B1 (de) * | 2001-01-08 | 2008-06-11 | CSL Behring GmbH | Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms |
DE10148037A1 (de) * | 2001-09-28 | 2003-04-17 | Aventis Behring Gmbh | Verwendung der den Blutgerinnungsfaktor VII aktivierenden Protease zur Prophylaxe und Therapie von vaso-proliferativen Erkrankungen |
DE10205520A1 (de) * | 2002-02-08 | 2003-08-14 | Aventis Behring Gmbh | Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease |
-
1999
- 1999-02-01 DE DE19903693A patent/DE19903693A1/de not_active Withdrawn
- 1999-04-08 DK DK99106913T patent/DK0952215T3/da active
- 1999-04-08 AT AT99106913T patent/ATE323157T1/de active
- 1999-04-08 EP EP99106913A patent/EP0952215B1/en not_active Expired - Lifetime
- 1999-04-08 ES ES99106913T patent/ES2262264T3/es not_active Expired - Lifetime
- 1999-04-08 DE DE69930778T patent/DE69930778T2/de not_active Expired - Lifetime
- 1999-04-21 US US09/295,316 patent/US6528299B1/en not_active Expired - Lifetime
- 1999-04-23 CA CA2269109A patent/CA2269109C/en not_active Expired - Lifetime
- 1999-04-23 KR KR1019990014636A patent/KR100776921B1/ko not_active IP Right Cessation
- 1999-04-23 JP JP11641199A patent/JP4361986B2/ja not_active Expired - Fee Related
- 1999-04-23 AU AU23935/99A patent/AU748221B2/en not_active Ceased
-
2002
- 2002-12-16 US US10/319,592 patent/US6911334B2/en not_active Expired - Lifetime
-
2005
- 2005-05-02 US US11/118,396 patent/US20050202002A1/en not_active Abandoned
-
2006
- 2006-09-29 KR KR1020060096156A patent/KR20060107736A/ko not_active Application Discontinuation
-
2007
- 2007-11-13 US US11/984,058 patent/US7879803B2/en not_active Expired - Fee Related
-
2009
- 2009-03-11 JP JP2009057232A patent/JP4422781B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2009131273A (ja) | 2009-06-18 |
EP0952215B1 (en) | 2006-04-12 |
US6528299B1 (en) | 2003-03-04 |
US7879803B2 (en) | 2011-02-01 |
CA2269109C (en) | 2010-06-15 |
US6911334B2 (en) | 2005-06-28 |
DE69930778T2 (de) | 2007-03-29 |
EP0952215A3 (en) | 2002-06-26 |
AU748221B2 (en) | 2002-05-30 |
KR19990083444A (ko) | 1999-11-25 |
US20080175878A1 (en) | 2008-07-24 |
ES2262264T3 (es) | 2006-11-16 |
JP2000023696A (ja) | 2000-01-25 |
JP4422781B2 (ja) | 2010-02-24 |
AU2393599A (en) | 1999-11-04 |
US20030152567A1 (en) | 2003-08-14 |
US20050202002A1 (en) | 2005-09-15 |
ATE323157T1 (de) | 2006-04-15 |
DE19903693A1 (de) | 1999-10-28 |
KR20060107736A (ko) | 2006-10-16 |
EP0952215A2 (en) | 1999-10-27 |
DE69930778D1 (de) | 2006-05-24 |
JP4361986B2 (ja) | 2009-11-11 |
KR100776921B1 (ko) | 2007-11-20 |
CA2269109A1 (en) | 1999-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0952215T3 (da) | Protease til aktivering af koaguleringsfaktor VII | |
BR0304600A (pt) | Curativo para ferimento e tecido hemostático e processos de produção e uso dos mesmos | |
PT939628E (pt) | Inibidores tiolsulfona de metaloproteases | |
PT94016A (pt) | Processo para a producao de inibidores de proteinases | |
KR970064594A (ko) | 노화방지용 화장품 조성물 | |
WO1996035788A3 (en) | Kunitz type protease inhibitors | |
BR0010758A (pt) | Aril e heteroaril pirimidinonas policìclicas substituìdas úteis como anti coagulantes | |
DK374286A (da) | Serinproteaseinhibitorer og fremgangsmaade til isolering af disse | |
AU639257B2 (en) | Proteins having anticoagulant properties | |
NO923737L (no) | Forbedret vevs-lim fremstilt ved anvendelse av kryopresipitat | |
BR0011295A (pt) | Aril e heteroaril pirazinonas policìclicas substituìdas úteis para inibição seletiva de cascata de coagulação | |
DE3587526T3 (de) | Serinproteaseinhibitoren und isolierungsverfahren dazu. | |
Zaganelli et al. | Purification and characterization of a fibrinogen-clotting enzyme from the venom of jararacuçu (Bothrops jararacussu) | |
WO1999063090A3 (en) | Protease inhibitor peptides | |
RU95105983A (ru) | Ингибиторы тромбина, способы их получения и фармацевтическая композиция на их основе | |
EP1497326A4 (en) | PROTHROMBIN ACTIVATING PROTEIN | |
PT1268463E (pt) | 4-pironas substituidas com arilo e heteroarilo policiclicos uteis para a inibicao selectiva da cascata de coagulacao | |
Eckle et al. | Protein S degradation in vitro by neutrophil elastase | |
DE3689927D1 (de) | Reagens und Verfahren. | |
WO2005037202A3 (en) | Methods for modulating angiogenesis | |
BR0213092A (pt) | Compostos heterocìclicos de 6 elementos úteis para a inibição seletiva da cascata de coagulação | |
ATE353666T1 (de) | Verwendung von aktiviertem gerinnungsfaktor vii zur behandlung von durch thrombolytische therapie-induzierten wichtigen blutungen | |
DE69810724D1 (de) | Verwendung von Protein C Inhibitor zur Behandlung disseminierter intravasaler Gerinnung (DIC) | |
DK1096951T3 (da) | Anvendelse af bromelainproteaser til inhiberingen af blodkoaguleringen | |
Weinstein et al. | Preliminary characteristics of the prothrombin converting enzyme from venom of Stephen's banded snake (Hoplocephalus stephensii) |